RU2019122996A - Комбинированная вакцина для свиней - Google Patents
Комбинированная вакцина для свиней Download PDFInfo
- Publication number
- RU2019122996A RU2019122996A RU2019122996A RU2019122996A RU2019122996A RU 2019122996 A RU2019122996 A RU 2019122996A RU 2019122996 A RU2019122996 A RU 2019122996A RU 2019122996 A RU2019122996 A RU 2019122996A RU 2019122996 A RU2019122996 A RU 2019122996A
- Authority
- RU
- Russia
- Prior art keywords
- pcv2
- vitamin
- acetate
- antigen
- oil
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 11
- 241000282887 Suidae Species 0.000 title claims 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 16
- 241001673669 Porcine circovirus 2 Species 0.000 claims 10
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 8
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims 8
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 8
- 229940032094 squalane Drugs 0.000 claims 8
- 229940042585 tocopherol acetate Drugs 0.000 claims 8
- 239000008346 aqueous phase Substances 0.000 claims 6
- 239000000839 emulsion Substances 0.000 claims 5
- 239000007764 o/w emulsion Substances 0.000 claims 5
- 230000003362 replicative effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 229940001442 combination vaccine Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 241001469654 Lawsonia <weevil> Species 0.000 claims 1
- 241001148567 Lawsonia intracellularis Species 0.000 claims 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (21)
1. Комбинированная вакцина, содержащая неспособный к воспроизведению антиген из цирковируса свиней типа 2 (PCV2) и живой вирус репродуктивного и респираторного синдрома свиней (PRRSV), отличающаяся тем, что вакцина представляет собой эмульсию масло-в-воде, содержащую сквалан и ацетат витамина E.
2. Комбинированная вакцина по п. 1, содержащая сквалан в количестве между приблизительно 1 и приблизительно 9% масс./об.
3. Комбинированная вакцина по пп. 1 или 2, содержащая ацетат витамина E в количестве между приблизительно 1 и приблизительно 10% масс./об.
4. Комбинированная вакцина по любому из пп. 1-3, где эмульсия масло-в-воде представляет собой субмикронную эмульсию.
5. Комбинированная вакцина по любому из пп. 1-4, также содержащая неспособный к воспроизведению антиген из Mycoplasma hyopneumoniae (Mhyo).
6. Комбинированная вакцина по любому из пп. 1-5, также содержащая неспособный к воспроизведению антиген из Lawsonia intracellularis (Lawsonia).
7. Набор из частей, содержащей по меньшей мере два контейнера: один контейнер, содержащий неспособный к воспроизведению антиген из PCV2 в эмульсии масло-в-воде, содержащей сквалан и ацетат витамина E; и один контейнер, содержащий живой PRRSV в лиофилизированной форме.
8. Способ получения комбинированной вакцины по любому из пп. 1-6, включающий стадии:
- получения водной фазы, содержащей неспособный к воспроизведению антиген из PCV2 и живой PRRSV, и
- смешивания указанной водной фазы с масляной эмульсией, содержащей сквалан и ацетат витамина E.
9. Способ получения комбинированной вакцины по любому из пп. 1-6, включающий стадии:
- получения живого PRRSV в лиофилизированной форме,
- получения водной фазы, содержащей неспособный к воспроизведению антиген из PCV2,
- смешивания указанной водной фазы с масляной эмульсией, содержащей сквалан и ацетат витамина E, и
- разведения указанного лиофилизированного живого PRRSV указанной смесью водной фазы и масляной эмульсии.
10. Способ получения комбинированной вакцины по любому из пп. 1-6, включающий стадии:
- получения смеси водной фазы, содержащей неспособный к воспроизведению антиген из PCV2, и масляной эмульсии, содержащей сквалан и ацетат витамина E, и
- разведения живого PRRSV в лиофилизированной форме указанной смесью.
11. Эмульсия масло-в-воде, содержащая сквалан и ацетат витамина E, неспособный к воспроизведению антиген из PCV2 и живой PRRSV, для использования в вакцинации свиней против PCV2 и PRRSV.
12. Применение неспособного к воспроизведению антигена из PCV2 и живого PRRSV, для изготовления комбинированной вакцины для свиней, отличающееся тем, что вакцина представляет собой эмульсию масло-в-воде, содержащую сквалан и ацетат витамина E.
13. Способ вакцинации свиней против PCV2 и PRRSV посредством введения указанным свиньям комбинированной вакцины по любому из пп. 1-6.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206789 | 2016-12-23 | ||
| EP16206789.6 | 2016-12-23 | ||
| EP17157828 | 2017-02-24 | ||
| EP17157828.9 | 2017-02-24 | ||
| PCT/EP2017/084376 WO2018115435A1 (en) | 2016-12-23 | 2017-12-22 | Combination vaccine for swine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019122996A true RU2019122996A (ru) | 2021-01-25 |
| RU2019122996A3 RU2019122996A3 (ru) | 2021-05-14 |
| RU2761453C2 RU2761453C2 (ru) | 2021-12-08 |
Family
ID=60955042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019122996A RU2761453C2 (ru) | 2016-12-23 | 2017-12-22 | Комбинированная вакцина для свиней |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11065324B2 (ru) |
| EP (1) | EP3558351B1 (ru) |
| JP (1) | JP6931059B2 (ru) |
| KR (1) | KR102632419B1 (ru) |
| CN (1) | CN110087678B (ru) |
| BR (1) | BR112019012504A2 (ru) |
| CA (1) | CA3045563C (ru) |
| DK (1) | DK3558351T3 (ru) |
| ES (1) | ES2906854T3 (ru) |
| MX (1) | MX388128B (ru) |
| PL (1) | PL3558351T3 (ru) |
| RU (1) | RU2761453C2 (ru) |
| WO (1) | WO2018115435A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1968630T5 (en) | 2005-12-29 | 2018-08-13 | Boehringer Ingelheim Vetmedica Inc | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS. |
| CN120771270A (zh) | 2017-12-04 | 2025-10-14 | 英特维特国际股份有限公司 | 具有复制子颗粒和油佐剂的疫苗 |
| GB2599572B (en) * | 2019-05-20 | 2023-09-20 | Soligenix Inc | Compositions and methods of manufacturing trivalent filovirus vaccines |
| MX2022003090A (es) * | 2019-09-12 | 2022-04-11 | Intervet Int Bv | Vacuna combinada para ser administrable intradermicamente. |
| US12448417B2 (en) | 2019-12-18 | 2025-10-21 | Intervet Inc. | Cryptosporidiosis vaccine |
| AR124849A1 (es) | 2021-02-11 | 2023-05-10 | Intervet Int Bv | Vacuna para mycoplasma bovis |
| JP2024536600A (ja) | 2021-10-25 | 2024-10-04 | インターベット インターナショナル ベー． フェー． | ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン |
| WO2023118553A1 (en) | 2021-12-24 | 2023-06-29 | Intervet International B.V. | Stable emulsions of antigens |
| CN117100851A (zh) * | 2023-10-23 | 2023-11-24 | 成都依思康生物科技有限公司 | 一种佐剂、疫苗组合物及其制备方法和应用 |
| WO2025093740A1 (en) | 2023-11-03 | 2025-05-08 | Intervet International B.V. | Recombinant pyolysin protein |
| WO2025262123A1 (en) | 2024-06-19 | 2025-12-26 | Intervet International B.V. | Veterinary vaccines against enteric diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE115862T1 (de) * | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| ES2367194T3 (es) * | 2005-11-04 | 2011-10-31 | Novartis Vaccines And Diagnostics S.R.L. | Cambio del equilibrio th1/th2 en vacunas contra la gripe fraccionadas con adyuvantes. |
| US9452209B2 (en) * | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| TWI449533B (zh) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗 |
| JP5778039B2 (ja) * | 2009-02-10 | 2015-09-16 | ノバルティス アーゲー | 流行関連株のためのインフルエンザワクチンレジメン |
| CN102395600B (zh) | 2009-02-17 | 2015-03-25 | 葛兰素史密斯克莱生物公司 | 含有无铝佐剂的灭活的登革热病毒疫苗 |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| DK3076997T3 (en) * | 2013-12-03 | 2018-12-10 | Intervet Int Bv | SVINEVACCINE v PRRS AND LAWSONIA INTRACELLULARIS |
| BR112017012220A2 (pt) | 2014-12-11 | 2018-01-30 | Intervet Int Bv | processos para preparar uma composição de antígeno e uma vacina, composição de antígeno, vacina, usos de uma composição de antígeno e de uma vacina, e, método para prevenção ou redução de infecção por um vírus em suíno e sinais associados à doença. |
| CN105251002B (zh) * | 2015-11-13 | 2019-02-15 | 中国人民解放军第三军医大学 | 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法 |
-
2017
- 2017-12-22 WO PCT/EP2017/084376 patent/WO2018115435A1/en not_active Ceased
- 2017-12-22 PL PL17828754T patent/PL3558351T3/pl unknown
- 2017-12-22 ES ES17828754T patent/ES2906854T3/es active Active
- 2017-12-22 US US16/471,606 patent/US11065324B2/en active Active
- 2017-12-22 CA CA3045563A patent/CA3045563C/en active Active
- 2017-12-22 MX MX2019007349A patent/MX388128B/es unknown
- 2017-12-22 DK DK17828754.6T patent/DK3558351T3/da active
- 2017-12-22 JP JP2019533381A patent/JP6931059B2/ja active Active
- 2017-12-22 CN CN201780080200.4A patent/CN110087678B/zh active Active
- 2017-12-22 RU RU2019122996A patent/RU2761453C2/ru active
- 2017-12-22 BR BR112019012504-3A patent/BR112019012504A2/pt active IP Right Grant
- 2017-12-22 KR KR1020197017612A patent/KR102632419B1/ko active Active
- 2017-12-22 EP EP17828754.6A patent/EP3558351B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2906854T3 (es) | 2022-04-20 |
| US20200085935A1 (en) | 2020-03-19 |
| MX2019007349A (es) | 2019-09-05 |
| JP2020514266A (ja) | 2020-05-21 |
| RU2761453C2 (ru) | 2021-12-08 |
| EP3558351A1 (en) | 2019-10-30 |
| CN110087678A (zh) | 2019-08-02 |
| BR112019012504A2 (pt) | 2019-11-19 |
| EP3558351B1 (en) | 2022-01-26 |
| RU2019122996A3 (ru) | 2021-05-14 |
| DK3558351T3 (da) | 2022-03-21 |
| US11065324B2 (en) | 2021-07-20 |
| CN110087678B (zh) | 2023-09-26 |
| PL3558351T3 (pl) | 2022-03-21 |
| MX388128B (es) | 2025-03-19 |
| KR102632419B1 (ko) | 2024-01-31 |
| WO2018115435A1 (en) | 2018-06-28 |
| CA3045563C (en) | 2022-05-03 |
| KR20190099418A (ko) | 2019-08-27 |
| JP6931059B2 (ja) | 2021-09-01 |
| CA3045563A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019122996A (ru) | Комбинированная вакцина для свиней | |
| UA114504C2 (uk) | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs | |
| RU2017124240A (ru) | СПОСОБ ПОЛУЧЕНИЯ ГОТОВОЙ К ПРИМЕНЕНИЮ КОМБИНИРОВАННОЙ ВАКЦИНЫ ПРОТИВ PCV2/M.hyo | |
| RU2014140106A (ru) | Комбинированная вакцина pcv/mycoplasma hyopneumoniae | |
| RU2014140107A (ru) | Вакцина mycoplasma hyopneumoniae | |
| CY1108994T1 (el) | Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα | |
| RU2016110430A (ru) | Pcv2b дивергентная вакцинная композиция и способы её применения | |
| CO6251273A2 (es) | Composiciones para vacuna en emulsion que comprenden antigeno y un adyuvante en la fase acuosa y su metodo de elaboracion | |
| RU2017101091A (ru) | Композиции вакцин с двойным адъювантом, получение и применения | |
| PE20201443A1 (es) | Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma | |
| CL2021002727A1 (es) | Vacuna con subunidades del vfpc | |
| Patil et al. | Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies | |
| WO2007052061A3 (en) | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines | |
| BR112022004256A2 (pt) | Vacina de combinação para administração intradérmica | |
| CN106692966B (zh) | 动物疫苗用佐剂及其制备方法和应用 | |
| PH12018501368A1 (en) | M hyo multivalent vaccine and uses thereof | |
| WO2015187969A3 (en) | Antibody guided vaccines and methods of use for generation of rapid mature immune responses | |
| JP6484241B2 (ja) | ＰＲＲＳおよびローソニア・イントラセルラリス（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）に対するブタワクチン | |
| WO2020012428A8 (en) | New vaccines against avian reoviruses | |
| MY207280A (en) | Polyvalent immunogenicity composition for human papillomavirus | |
| CN102813922B (zh) | 一种复方油佐剂及其制备方法和应用 | |
| BRPI0608310A2 (pt) | uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos | |
| BR112023018838A2 (pt) | Composições de vacina e métodos para uso das mesmas | |
| JPWO2023118553A5 (ru) | ||
| Goodarzi et al. | Innovations, challenges, and gaps in the development of an effective vaccine against Neisseria gonorrhoeae, a narrative review |